Skip to content
Clinical Trials – home

Medical Center Akad. Iv. Penchev EOOD

Verified siteinfo

Bulgaria Ulitsa Zdrave 2, 1431 Sofia, Bulgaria

  • 7 trials recruiting
  • Obesity · Hypertriglyceridaemia · Type 2 diabetes mellitus
  • Adults and children

About Specializations

Medical Center Akad. Iv. Penchev EOOD in Sofia, Bulgaria specialises in clinical trials of conditions such as Obesity, Hypertriglyceridaemia, Type 2 diabetes mellitus, Acromegaly, and other specialisations. This site conducts important research.

Main research areas of the site

Dermatology and Immunology

The medical center is at the forefront of dermatology and immunology, focusing on innovative treatments for Chronic Inducible Urticaria. This condition, characterized by its unpredictable nature, requires advanced therapeutic approaches to manage symptoms effectively.

  • Chronic Inducible Urticaria (CIndU)
  • Cold Urticaria (ColdU)
  • Symptomatic Dermographism (SD)

Through rigorous research, the center is pioneering new methodologies to improve patient outcomes, particularly for those who are refractory to traditional H1-antihistamines.

Nephrology and Metabolic Disorders

Specializing in nephrology and metabolic disorders, the center is dedicated to advancing the treatment of Chronic Kidney Disease (CKD), especially in patients with comorbid conditions such as Type 2 diabetes and obesity.

  • Chronic Kidney Disease (CKD)
  • Type 2 Diabetes
  • Obesity

By exploring the dose-response relationship of novel therapeutics, the center aims to significantly reduce kidney damage and improve the quality of life for affected individuals.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ulitsa Zdrave 21431 SofiaBulgaria
Recruiting now
7 trials
Conditions studied
14
Partner status
Verified site

More sites in SofiaBulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

24 clinical trials

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Sponsor:Novo Nordisk A/S

Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Efficacy and safety of osilodrostat with drug combination in patients with hypertension caused by Cushing's syndrome

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Recordati AG

Graves' disease

Recruiting

Long-Term Study of Imeroprubart in Adults With Graves' Disease

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Graves' disease

Recruiting

Study of IMVT-1402 Treatment for Adults with Graves' Disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Study of plozasiran to prevent acute pancreatitis in adults with severe hypertriglyceridemia

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Acromegaly

Recruiting

Study of Debio 4126, a new octreotide formulation, compared to placebo in patients with acromegaly who were previously treated with somatostatin analogs

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Debiopharm International SA

Obesity

Not yet recruiting

KAI-9531 in Adults With Obesity or Overweight and Diabetes

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:HRS 9531

Bacterial infection

Not yet recruiting

Study on Cefiderocol for Treating Gram-negative Bacterial Infections in Hospitalized Infants Under 3 Months

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:Cefiderocol
  • Sponsor:Shionogi B.V.

Hypertriglyceridaemia

Not recruiting

Long-Term Safety Study of Plozasiran for Adults with High Triglycerides

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Hypertriglyceridaemia

Not recruiting

Study to Evaluate Plozasiran for Adults with High Triglycerides

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Study on the Effects of Semaglutide on Diabetic Eye Disease in People with Type 2 Diabetes

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.